Levodopa en la enfermedad de Parkinson: ¿Qué hemos aprendido?

Juri, Carlos; C, Pedro Chaná

doi:10.4067/s0034-98872006000700014

Cited by 10 publications

(10 citation statements)

References 42 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, energy consumption in the studied population is appropriate. Studies were conducted to evaluate the PD patients diet and the interference in the pharmacologic therapy (4,9,19,24,25). However, the number of different methodologies and the variety of sample populations do not provide any conclusive evidence to which is the best nutritional therapy for these patients in order to be able to relate the use of levodopa and other drugs (4,6,8,10,18).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Protein intake and the use of levodopa in patients with Parkinson's disease

et al. 2013

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Parkinson's disease (PD) is a disorder caused by degeneration of dopaminergic neurons in the nigrostriatal pathway (1-3), resulting in a decrease of dopamine production in this region (4). The causes of degeneration are not yet fully elucidated.…”

Section: Introductionmentioning

confidence: 99%

Protein intake and the use of levodopa in patients with Parkinson's disease

et al. 2013

View full text Add to dashboard Cite

“…Paula Pinheiro Gerszt (1), Cintia Rodrigues Baltar (2) , Anderson Evangelista dos Santos (3) , Adriana Leico Oda (4) (1) Phonoaudiologist; Administrative Technician in Education of the Federal University of the Espírito Santo; Skilled in Dysphagia by CEFAC-RJ. (2) Phonoaudiologist by Federal University of the Rio de Janeiro, Phonoaudiologist in the Clementino Fraga Filho Universitary Hospital -CFFUH and in the Getulio Vargas State Hospital; Skilled in dysphagia by CEFAC -RJ.…”

Section: Interferência Do Tratamento Medicamentoso Imediato E Tardio mentioning

confidence: 99%

“…(2) Phonoaudiologist by Federal University of the Rio de Janeiro, Phonoaudiologist in the Clementino Fraga Filho Universitary Hospital -CFFUH and in the Getulio Vargas State Hospital; Skilled in dysphagia by CEFAC -RJ.…”

Section: Interferência Do Tratamento Medicamentoso Imediato E Tardio mentioning

confidence: 99%

“…The Parkinson disease is the second neurodegenerative infirmity more common after Alzheimer disease, affects mainly of the third age population 1,2 , with incidence,principally in the population up to 65 years old, and prevalence of 1 to 2% in the world and 3% in the Brazil 3 . Of unknow etiology, is characterized by presence of multiple monoaminergic dysfunction, including the deficit of dopaminergic classic and/or secondary manifestations to the use of dopaminomimetic drugs, a relevant subject to the clinical thinking in the phonoaudiologic evaluation and management, considering the risks of bronchoaspiration, dehydration and/or proteic-caloric desnutrition in the Parkinson disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Interferência do tratamento medicamentoso imediato e tardio na doença de Parkinson no gerenciamento da disfagia

et al. 2014

View full text Add to dashboard Cite

A Doença de Parkinson apresenta grande incidência na população idosa, gerando comprometimento motor progressivo, que afeta várias funções, dentre as quais se destaca a deglutição. Esse trabalho teve como objetivo relacionar a disfagia na Doença de Parkinson aos efeitos imediatos e/ou tardios do tratamento medicamentoso, que de forma direta ou indireta interferirá no gerenciamento fonoaudiológico. Fizemos uma revisão de literatura nas bases de dados eletrônicas Lilacs, Scielo, Medline e Pubmed no período de 2001 a 2011, utilizando os termos livres “Doença de Parkinson”; (Parkinson Disease), “deglutição”; (deglutition), “disfagia”; (dysphagia), “preparações farmacêuticas”; (pharmaceutical preparations), “levodopa”;, “videofluoroscopia”; (videofluoroscopy), além de um documento governamental (OPAS, 2002), artigos relevantes e exemplares da literatura americana e brasileira sobre o tema. A literatura aponta a Levodopa como o principal tratamento farmacológico da doença de Parkinson. Contudo, a melhora dos sintomas motores deve ser ponderada em função da ocorrência de efeitos colaterais importantes, sejam imediatos ou tardios. Até o momento não há respostas consistentes a favor da melhora da disfagia como resultado do tratamento farmacológico, cujos efeitos podem interferir direta ou indiretamente sobre as manifestações disfágicas e de várias formas. Assim, torna-se fundamental o registro das medicações como parte da anamnese, considerando que tais dados possam auxiliar na orientação/reorientação da conduta fonoaudiológica, especialmente em contexto interdisciplinar. A despeito da possibilidade do doente de Parkinson responder de forma inconsistente à terapia farmacológica, vale ressaltar que o profissional deve estar atento à presença de efeitos colaterais como fatores modificadores do quadro de disfagia orofaríngea na Doença de Parkinson idiopática.

show abstract

Functional disconnection of the substantia nigra pars compacta from the pedunculopontine nucleus impairs learning of a conditioned avoidance task

Bortolanza

Wietzikoski

Boschen

et al. 2010

Neurobiology of Learning and Memory

View full text Add to dashboard Cite

The pedunculopontine tegmental nucleus (PPTg) targets nuclei in the basal ganglia, including the substantia nigra pars compacta (SNc), in which neuronal loss occurs in Parkinson's disease, a condition in which patients show cognitive as well as motor disturbances. Partial loss and functional abnormalities of neurons in the PPTg are also associated with Parkinson's disease. We hypothesized that the interaction of PPTg and SNc might be important for cognitive impairments and so investigated whether disrupting the connections between the PPTg and SNc impaired learning of a conditioned avoidance response (CAR) by male Wistar rats. The following groups were tested: PPTg unilateral; SNc unilateral; PPTg-SNc ipsilateral (ipsilateral lesions in PPTg and SNc); PPTg-SNc contralateral (contralateral lesions in PPTg and SNc); sham lesions (of each type). SNc lesions were made with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine HCl (MPTP, 0.6 μmoles); PPTg lesions with ibotenate (24 nmoles). After recovery, all rats underwent 50-trial sessions of 2-way active avoidance conditioning for 3 consecutive days. Rats with unilateral lesions in PPTg or SNc learnt this, however rats with contralateral (but not ipsilateral) combined lesions in both structures presented no sign of learning. This effect was not likely to be due to sensorimotor impairment because lesions did not affect reaction time to the tone or footshock during conditioning. However, an increased number of non-responses were observed in the rats with contralateral lesions. The results support the hypothesis that a functional interaction between PPTg and SNc is needed for CAR learning and performance.

show abstract

Levodopa en la enfermedad de Parkinson: ¿Qué hemos aprendido?

Cited by 10 publications

References 42 publications

Protein intake and the use of levodopa in patients with Parkinson's disease

Protein intake and the use of levodopa in patients with Parkinson's disease

Interferência do tratamento medicamentoso imediato e tardio na doença de Parkinson no gerenciamento da disfagia

Functional disconnection of the substantia nigra pars compacta from the pedunculopontine nucleus impairs learning of a conditioned avoidance task

Contact Info

Product

Resources

About